Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | AGXT | P21549 | 1/20 | 0.40 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5373022 | 0.74 | ADH1B (0.42) | MEN1KMT2A | |
| SCHEMBL1176902 | 0.70 | CYP2A6 (0.62) | CYP2A6ADRB2AGXTASIC3LOXL2 | |
| SCHEMBL15961524 | 0.70 | CYP2A6 (0.67) | CYP2A6ADRB2AGXTASIC3LOXL2 | |
| SCHEMBL7059655 | 0.69 | TSHR (0.41) | MEN1KMT2A | |
| SCHEMBL27470182 | 0.69 | CYP2A6 (0.56) | CYP2A6ADRB2AGXTASIC3LOXL2 | |
| SCHEMBL7061210 | 0.69 | SMN1; SMN2 (0.42) | MEN1KMT2A | |
| SCHEMBL1254283 | 0.68 | CYP2A6 (1.00) | CYP2A6ADRB2AGXTASIC3LOXL2 | |
| SCHEMBL5767231 | 0.68 | CHRM2 (0.44) | MEN1KMT2A | |
| SCHEMBL7061205 | 0.66 | RAB9A (0.40) | — | |
| SCHEMBL6762362 | 0.66 | RIPK1 (0.37) | MEN1KMT2AKDM4CPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162783-A1 | Method and composition for the treatment of pain | ASTRAZENECA AB (SE) | 2003-08-28 | — | — | US | disclosed |
| EP-1248621-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001047523-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162783-A1 | Method and composition for the treatment of pain | OPRK1, OPRD1, ACHE | CYP2A6 394/4885ADRB2 44/4885AGXT 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.